Topics:

Diabetes Type 2

SGLT2 Inhibitor Q & A

Four questions for you to answer, four facts you need to know.

 

Diabetes Type 2

Microbes in the gut affect metabolic pathways involved in the pathogenesis of obesity, insulin resistance, and diabetes. Antibiotics can alter gut microbiota.

Aflibercept (Eylea, Regeneron Pharmaceuticals), a second ophthalmic vascular endothelial growth factor inhibitor, has received FDA approval for the treatment of diabetic retinopathy in patients with diabetic macular edema.

A Danish study found reduced endogenous levels of glucagon-like peptide-1 in persons with prediabetes. Perhaps the incretin system defect comes first.

Conditions associated with long-term diabetes affect myriad organs and systems. Which one of these comorbidities is not associated with the disease?

What are some of the esophageal complications seen in patients with long-standing hyperglycemia?

GLP-1 RA, cardioprotection

Glucagon-like peptide-1 receptor agonists represent a novel class of antihyperglycemic agents that have a cardiac-friendly profile.

Examining ethnic patterns of prevalent geriatric conditions in diabetes may help ensure culturally competent, patient-centered care in an increasingly diverse population.

Pages

Subscribe to Diabetes Type 2 on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.